Vitamin K2 May Slow Coronary Calcification in High-Risk Patients, but Clinical Benefits Remain Unproven

Published: June 28, 2026

LONDON — A new randomized controlled trial suggests that two years of daily vitamin K2 and D supplementation may modestly slow the progression of coronary artery calcification (CAC) in certain men with symptomatic coronary artery disease. However, researchers emphasize that the overall effect was small, confined primarily to a high-risk subgroup, and its real-world ability to prevent heart attacks or extend life remains entirely unproven. The findings, published online and highlighted by Medscape, add another layer of complexity to the ongoing debate over whether dietary supplements can meaningfully alter the course of cardiovascular disease.

Vascular calcification—the buildup of calcium deposits in the plaque of artery walls—is a hallmark of aging and advanced atherosclerosis (hardening of the arteries). While a higher calcium score heavily correlates with a greater risk of adverse cardiac events, the medical community remains divided on whether actively slowing this calcification process translates into a safer, more stable artery environment.

What the Study Found: A Subgroup Signal

The clinical trial analyzed data from 304 older men (average age 71) derived from a broader study population of 389 participants. Over a 24-month period, participants were randomized to receive either a combination of vitamin K2 and vitamin D supplements or a matching placebo. Researchers monitored changes in their coronary artery calcium burden using high-resolution CT scans at the start of the study and at the two-year mark.

The results revealed a modest but statistically significant difference in how fast the calcium accumulated between the two groups. In the supplementation group, the median CAC score rose from 135 to 184 Agatston units (AU)—a standard metric used to quantify calcium on CT scans. In comparison, the placebo group saw their median score jump from 145 to 214 AU.

Median Coronary Artery Calcium (CAC) Progression Over 24 Months
===========================================================
Supplement Group (K2 + D):   135 AU -------> 184 AU (+49 AU)
Placebo Group:               145 AU -------> 214 AU (+69 AU)
===========================================================

The mathematical benefit was more pronounced among individuals who began the trial with heavier calcification. For the specific subgroup of patients with baseline CAC scores of 400 or higher—a threshold indicating an advanced burden of disease—the supplement group experienced a lower mean progression compared to the placebo arm, yielding a between-group difference of 92 AU over the two years.

Despite these mathematical differences, the trial’s authors urged caution. The overall effect across the entire study group was small, and the percentage of patients classified as “fast progressors”—those whose calcium scores accelerated dangerously fast—did not differ significantly between the two groups. Crucially, the trial found no significant difference in the progression of noncalcified plaque, which represents the softer, volatile fatty deposits more prone to rupturing and triggering sudden heart attacks.

Biological Plausibility vs. Clinical Reality

The scientific interest in vitamin K2 stems from its specific role in human calcium metabolism. While vitamin K1 is primarily used by the liver to regulate blood clotting, vitamin K2 (menaquinone) is utilized by peripheral tissues, including the blood vessels and bones.

Vitamin K2 acts as an essential cofactor to activate matrix Gla protein (MGP), a potent local inhibitor of vascular mineralization. When adequately carboxylated (activated) by vitamin K2, MGP binds to calcium crystals and prevents them from depositing into the soft tissue of the arterial walls.

The Diagnostic Trap: While slowing down a calcium score seems highly beneficial on paper, a lower calcium score does not automatically guarantee fewer heart attacks. In some instances, dense calcification actually stabilizes a fatty plaque, making it less likely to rupture.

“We have to distinguish between a biological mechanism and a proven clinical benefit,” says Dr. Jane Foster, a preventive cardiologist at the Metropolitan Heart Institute, who was not involved in the trial. “Slowing down the accumulation of calcium is a fascinating surrogate marker. It tells us the biology is active. But what patients care about—and what doctors need to see—is a reduction in actual heart attacks, fewer hospitalizations, and improved survival. This trial simply wasn’t large enough or long enough to measure those outcomes.”

The Broader Scientific Context: A Mixed Track Record

This trial is not the first to explore the relationship between vitamin K2 and vascular health, and the broader medical literature counsels strict moderation.

The findings echo data from a similar randomized analysis published in JACC Advances, which also noted no overall reduction in mean CAC progression with vitamin K2 and D, though it highlighted a similarly speculative, hypothesis-generating signal in a high-calcium subgroup.

Conversely, other clinical environments have yielded completely flat results. A well-regarded randomized controlled trial investigating the effect of vitamin K2 on vascular calcification in hemodialysis patients found that while the supplement successfully improved laboratory biomarkers of vitamin K status, it failed to reduce vascular calcification progression or lower major adverse cardiac outcomes over an 18-month observation period.

Notable Study Limitations

To maintain journalistic and scientific balance, several limitations within the study’s design must be taken into account:

• Highly Selected Sample: The trial was relatively small and consisted entirely of older men (average age 71). Furthermore, a significant portion of eligible patients declined to participate, creating a potential selection bias that limits how well these findings apply to women or younger populations.

• Confounding Ingredients: The active supplement combined both vitamin K2 and vitamin D. Because vitamin D plays its own integral, complex role in bone metabolism and calcium regulation, it is impossible to attribute the noted effects to vitamin K2 alone.

• Unmeasured Variables: The research team did not track the participants’ baseline dietary intake of vitamin K-rich foods (such as fermented cheeses or natto), nor were they able to assess microcalcifications—the microscopic flecks of calcium that occur early in plaque development and are thought to be highly unstable.

What This Means for Consumer Health Decisions

For health-conscious consumers and patients managing cardiovascular disease, the practical takeaway from this study is one of disciplined caution rather than immediate action.

For individuals currently taking over-the-counter vitamin K2 supplements because of retail labels promising “artery support” or “cardiovascular clearing,” this study provides interesting food for thought, but it does not validate those sweeping commercial claims.

More importantly, medical experts stress that vitamin K2 must never be viewed as a substitute for established, multi-decade medical interventions that possess hard outcome data. Proven strategies—including statin therapy to lower LDL cholesterol, rigorous blood pressure control, smoking cessation, regular physical exercise, and structured diabetes management—remain the absolute bedrock of cardiovascular prevention.

Established Cardiovascular Interventions vs. Experimental Supplements
===================================================================
[STATINS / LIFESTYLE] ------------> Hard Evidence: Reduces Heart Attacks & Death
[VITAMIN K2 SEPARATE] -----------> Experimental: Modest Influence on CT Calcium Only
===================================================================

Finally, specific patient populations must exercise extreme caution. Vitamin K is a powerful biological agent involved in coagulation. Individuals taking vitamin K antagonists, such as the blood thinner warfarin, should strictly avoid vitamin K2 supplementation, as it can directly counteract their medication and increase the risk of dangerous blood clots or strokes. Always discuss any over-the-counter supplement changes directly with your treating physician.

References

• https://www.medscape.com/viewarticle/vitamin-k2-supplementation-may-curb-coronary-artery-2026a1000lt1

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.